Perspective Therapeutics (CATX) Cash & Equivalents (2010 - 2026)

Perspective Therapeutics has disclosed Cash & Equivalents across 17 years of filings, most recently posting $270.9 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $270.9 million, up 27.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $270.9 million (up 27.96% YoY), and the FY2025 annual result was $30.6 million, down 50.26% from the prior year.
• Cash & Equivalents came in at $270.9 million for Q1 2026 at Perspective Therapeutics, up from $30.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $270.9 million in Q1 2026 to a low of $9.2 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $55.9 million (2022), against an average of $100.1 million.
• Across the five-year window, Cash & Equivalents soared 1389.18% in 2024 and plunged 90.01% in 2025, its largest moves.
• Perspective Therapeutics' Cash & Equivalents stood at $21.0 million in 2022, then plunged by 55.99% to $9.2 million in 2023, then soared by 566.59% to $61.6 million in 2024, then plunged by 50.26% to $30.6 million in 2025, then jumped by 784.46% to $270.9 million in 2026.
• The last three Cash & Equivalents figures came in at $270.9 million (Q1 2026), $30.6 million (Q4 2025), and $26.8 million (Q3 2025), per Business Quant data.